A Review of 177Lutetium-PSMA and 225Actinium-PSMA as Emerging Theranostic Agents in Prostate Cancer

The development of prostate-specific membrane antigen (PSMA) ligands labeled with radionuclides is a ground-breaking achievement in the management of prostate cancer. With the increasing use of (68)Gallium-PSMA and (18)F-DCFPyL (Pylarify) and their approval by the Food and Drug Administration (FDA),...

Descripción completa

Detalles Bibliográficos
Autores principales: Alam, Mohammad R, Singh, Shashi B, Thapaliya, Shreeya, Shrestha, Shreeya, Deo, Sulav, Khanal, Kishor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Radiation Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584169/
https://www.ncbi.nlm.nih.gov/pubmed/36284803
http://dx.doi.org/10.7759/cureus.29369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584169/
https://www.ncbi.nlm.nih.gov/pubmed/36284803
http://dx.doi.org/10.7759/cureus.29369

Ejemplares similares